Across TCGA pan-cancer cohorts, RPL26P9 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RPL26P9’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where RPL26P9 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL26P9 is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

COAD, STAD, and LIHC are the cancer types where RPL26P9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL26P9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	II,III,IV	−0.045	.016	4	view →
STAD	Male	IV	+0.265	<.001	1	view →
LIHC	Male	All	+0.021	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RPL26P9 RNA expression & survival · all RPL26P9 data types